Thirteen years after they first teamed up, AstraZeneca and Silence are giving their partnership another shot with a new $80 million deal to develop siRNA therapeutics targeting the liver and extrahepatic tissues. The deal is...

Antibody-drug conjugate company Immunomedics Inc. (NASDAQ:IMMU) hired Loretta Itri as CMO. She was EVP of global health sciences and regulatory affairs at The Medicines Co. (NASDAQ:MDCO). Shanghai-based diabetes company Hua Medicine Ltd. (HKEX:2552) hired Fuxing...

CAR T therapy company Allogene Therapeutics Inc . (NASDAQ:ALLO) hired Rafael G. Amado as EVP of R&D and CMO, effective Sept. 3. He was president of R&D at Adaptimmune Therapeutics plc (NASDAQ:ADAP). Allogene Executive Chairman and...

Mallinckrodt licenses RNAi candidate from Silence  Mallinckrodt plc (NYSE:MNK) obtained an exclusive, worldwide license to C3-targeted RNAi therapy SLN500 from Silence Therapeutics plc (LSE:SLN), plus options to license up to two additional complement-targeted preclinical candidates....

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said John Curnutte will retire as EVP and head of R&D on May 17 after eight years at the hematology company. SVP of Research Pamela Conley will lead research activities, effective...

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...

The board of Merck & Co. Inc. (NYSE:MRK) rescinded a 28-year-old policy that required CEOs to retire at age 65. CEO Kenneth Frazier, who turns 65 in December 2019, has agreed to stay in his...

RNA therapeutics company Silence Therapeutics plc (LSE:SLN) hired David Horn Solomon as CEO. He was CEO at Akari Therapeutics plc (NASDAQ:AKTX). Immuno-oncology company Apeiron Biologics AG (Vienna, Austria) said CEO Hans Loibner has retired. The...

Neuromuscular disease company Sarepta Therapeutics Inc. (NASDAQ:SRPT) hired Louise Rodino-Klapac as VP of gene therapy at its newly created gene therapy unit. She will continue to serve as acting CSO at Myonexus Therapeutics Inc. (New...